Samsung Biopharmaceuticals Holdings Co., Ltd.: The subsidiary Samsung Biopharmaceuticals signed an exclusive supply agreement under the Brazilian government's rare disease treatment program to supply SB12, a biosimilar of eculimab.

Zhitongcaijing · 3d ago
Samsung Biopharmaceuticals Holdings Co., Ltd.: The subsidiary Samsung Biopharmaceuticals signed an exclusive supply agreement under the Brazilian government's rare disease treatment program to supply SB12, a biosimilar of eculimab.